Tema Sinergie Acquires Majority Stake In Aseptic Filling OEM 6Bio

Faenza (Italy) / Barcelona (Spain) – TEMA Sinergie S.p.A., a global leader in isolation systems for the Radiopharma and Biotech Pharma industries, today announced the acquisition of a majority stake in 6Bio, a Spanish company specialized in high-performance aseptic filling technology.

The transaction is part of a strategic co-investment with EMERGE 4Life Partners, a European investment platform focused on the Life Sciences sector.

This initiative further strengthens Tema Sinergie’s position as a leading provider of advanced, end-to-end production systems. The partnership is designed to accelerate 6Bio’s industrial growth by combining Tema Sinergie’s expertise in isolation and containment technologies with Emerge 4Life Partners’ active investment approach and deep operational experience.

The acquisition significantly expands Tema Sinergie’s technological and strategic portfolio. 6Bio’s know-how in high-precision aseptic filling systems for small- and mid-scale production batches perfectly complements Tema Sinergie’s core competencies, enabling the company to deliver integrated solutions that meet the growing demand for greater productivity and flexibility—fully compliant with cGMP/FDA standards—particularly in the fast-growing Radiopharma and Biotech Pharma markets.

Through this co-investment, Emerge 4Life Partners reinforces its role as a growth-enabling platform. The firm will leverage its expertise in international business development and industrial scale-up for aseptic and radiopharmaceutical manufacturing, helping transform a niche technology into a scalable global business.

The collaboration will position 6Bio as a European leader in aseptic technology, delivering innovative, compliant, and efficient solutions to meet the increasing global demand for sterile and radiopharmaceutical production systems.

“We are extremely proud of this agreement. The integration will allow us to develop and offer unique market solutions with a special focus on the Biotech Pharma sector and the mid-term needs of the Radiopharma market. This synergy of technology, know-how, investment, and manufacturing excellence lays the foundation for innovative projects that anticipate future market needs,” said the companies in a joint statement.

About TEMA Sinergie

Founded in 1985 in Faenza, Italy, TEMA Sinergie is a global leader in containment, isolation, and radiopharma technologies, providing high-quality solutions for the pharmaceutical and nuclear medicine (Radiopharma) industries.

About EMERGE 4Life Partners

EMERGE 4Life Partners is a European private investment platform focused on the Life Sciences and advanced manufacturing industries. The firm supports growth-stage companies through capital investment, strategic expertise, and hands-on operational engagement.